← Back to Search

Predictive Analytics and Behavioral Nudges for Advanced Cancer

N/A
Waitlist Available
Led By Sandhya Mudumbi
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Summary

This trial seeks to improve palliative care access for cancer patients, which can improve symptom burden, quality of life, and survival.

Who is the study for?
This trial is for medical oncologists and advanced practice providers at Tennessee Oncology, treating patients with stage III or IV lung and non-colorectal GI cancers. Eligibility is determined using specific diagnosis codes, electronic health records (EHR), and manual screening.Check my eligibility
What is being tested?
The study tests if nudges in the EHR can increase palliative care use among advanced cancer patients. Practices are randomly assigned to either receive algorithm-based default referrals for palliative care or continue usual care without these prompts.See study design
What are the potential side effects?
Since this trial involves behavioral nudges rather than medications, there aren't direct physical side effects like those seen with drugs. However, changes in workflow or decision-making processes could occur.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Palliative Care Utilization in High-risk Patients
Secondary outcome measures
Palliative Care Utilization in Non-high Risk Patients
Other outcome measures
Aggressive end-of-life care via hospice enrollment
Aggressive end-of-life care via systemic therapy receipt
Change in Quality of Life
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports. Clinicians in the intervention arm will receive an EHR nudge with option to opt-out for palliative care referral for any eligible high-risk patient.
Group II: ControlActive Control1 Intervention
Clinicians of patients in both arms will receive education on the availability of early palliative care and performance reports. Clinicians will receive no further interventions beyond usual practice.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,354 Total Patients Enrolled
Tennessee Oncology, PLLCUNKNOWN
Abramson Cancer Center at Penn MedicineLead Sponsor
396 Previous Clinical Trials
147,399 Total Patients Enrolled

Media Library

Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05590962 — N/A
Cancer Research Study Groups: Control, Intervention
Cancer Clinical Trial 2023: Intervention Highlights & Side Effects. Trial Name: NCT05590962 — N/A
Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05590962 — N/A
~213 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top